TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline
TORL BioTherapeutics secured $158M in Series B-2 financing, led by Deep Track Capital, to advance its clinical-stage ADCs targeting CLDN 6+, CLDN 18.2+, CDH17+, and DLK1+ solid tumors. The funding supports pivotal trials for TORL-1-23 in platinum-resistant ovarian cancer and other programs, aiming to deliver breakthrough therapies for cancer patients.
Related Clinical Trials
Reference News
TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline
TORL BioTherapeutics secured $158M in Series B-2 financing, led by Deep Track Capital, to advance its clinical-stage ADCs targeting CLDN 6+, CLDN 18.2+, CDH17+, and DLK1+ solid tumors. The funding supports pivotal trials for TORL-1-23 in platinum-resistant ovarian cancer and other programs, aiming to deliver breakthrough therapies for cancer patients.